NeoGenomics, a Fort Myers-based provider of cancer-focused genetics testing services and global oncology contract research services, reported a $37 million net loss in the third quarter of 2022, according to an earnings report. That compares to a $20 million net loss for the third quarter of 2021. Consolidated revenue for the third quarter of 2022 was $129 million, a 6% increase over the same period last year. Clinical test volume decreased by 1% year-over-year, while average revenue per clinical test increased by 5% to $392. Pharma Services revenue increased by 18% to $23 million compared to the third quarter of 2021. Operating expenses for the third quarter of 2022 were $88 million, an increase of $1 million compared to the third quarter of 2021. This increase was primarily due to higher payroll and payroll-related costs.